Kenvue’s nightmare just got worse — the stock’s down 13% as thousands sue over baby powder in the U.K. and the White House eyes a review linking Tylenol to autism risk. With lawsuits piling up, an interim CEO, layoffs, and activist investors circling, the once “safe” consumer-health giant looks anything but steady.